Emerging Therapy Research
PsychoGenics is a pioneering preclinical CRO, and we are proud to offer advanced support for our partners at the forefront...
Preclinical Spinal Cord Injury Studies
PsychoGenics is at the forefront of preclinical spinal cord injury (SCI) research, and we are dedicated to fostering the development...
Disease Foundations
At PsychoGenics, we understand the complexities disease research foundations encounter in their pursuit of developing treatments. Our decades-long partnerships with...
PsychoGenics Achieves Top Supplier Status on Scientist.com for 2023
PGI is pleased to be recognized by scientist.com as a top marketplace supplier for 2023.
PsychoGenics Inc. Awarded $3 million SBIR Grant to Employ its AI-enabled Platforms to Find Treatments for Rare Disorders
PARAMUS, NEW JERSEY, August 28, 2024 – PsychoGenics, a leader in AI-enabled phenotypic drug discovery, has been awarded a Fast Track...
Preclinical Mental Illness Research
PsychoGenics stands at the forefront of preclinical mental illness research. Our state-of-the-art facilities, coupled with predictive rodent models and a...
Neurodevelopmental Disorders Research
Backed by extensive experience, our scientists possess the deep understanding needed to design and execute early-stage preclinical neurodevelopmental disorders studies....
Preclinical Neuromuscular Disorders Research
PsychoGenics is at the forefront of preclinical neuromuscular disorders research, combining long-standing expertise with advanced scientific tools. Our dedication to...